SURFACE LOGIX REPORTS DATA ON SLX-2101

Surface Logix has reported the results of a study of SLx-2101, the company's novel, long acting PDE-5 inhibitor for the management of disorders associated with endothelial dysfunction, including erectile dysfunction.

The Phase I study demonstrated that SLx-2101 has a favorable safety, tolerability, pharmacokinetic and pharmacodynamic profile in healthy male volunteers. SLx-2101 is now completing a Phase IIa trial in patients with erectile dysfunction.